leadf
logo-loader
viewCardiol Therapeutics

Cardiol Therapeutics closes $17.25M offering to boost pharmaceutical CBD commercialization efforts

The bought deal offering included the full exercise of the over-allotment option, which boosted the financing from its previously announced $15 million offering

Cardiol Therapeutics -
Cardiol sold a total of 6.9 million units priced at $2.50 and comprised of one share and one-half of one warrant exercisable at $3.25 for a 24-month period

Cardiol Therapeutics Inc (TSE:CRDL) closed $17.25 million in financing on Thursday to support the commercialization of its pharmaceutical cannabinoid products.

The bought deal offering included the full exercise of the over-allotment option, which boosted the financing from its previously announced $15 million offering.

The Oakville, Ontario-based company produces cannabidiol products, such as its lead drug CardiolRx, to treat heart disease and other cardiovascular conditions.

READ: Cardiol Therapeutics to raise $15 million to support CardiolRx commercialization

Closing the deal positions Cardiol to execute on its strategy to address “significant opportunities” in healthcare, according to Cardiol’s CEO David Elsley.

"As we all adjust to the new reality of operating during a global pandemic, Cardiol is fortunate to have the opportunity to collaborate with leading international researchers to develop new therapies to address inflammation in heart failure and in other cardiovascular abnormalities, and through this work explore the possibility of improving outcomes in high-risk COVID-19 patients,” Elsley said in a statement.

“There is increasing recognition that COVID-19 involves the heart and blood vessels, with excessive levels of inflammation. We also look forward to the commercial introduction of our lead product through our national supplier agreement with Medical Cannabis by Shoppers, a subsidiary of Shoppers Drug Mart."

Under the terms of the offering, Cardiol sold a total of 6.9 million units priced at $2.50 and comprised of one share and one-half of one warrant exercisable at $3.25 for a 24-month period. The warrants are subject to an acceleration right exercisable by the company if the daily volume-weighted average trading price of the shares is greater than $4.50 for 10 consecutive days.

A portion of the funds raised will also go towards Cardiol’s ongoing research and development programs, additional product development, and general working capital.

The deal was completed by a syndicate of underwriters led by Canaccord Genuity Corp and included Raymond James Ltd, AltaCorp Capital Inc, and Echelon Wealth Partners Inc.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: Cardiol Therapeutics

Price: 3 CAD

TSX:CRDL
Market: TSX
Market Cap: $98.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cardiol Therapeutics named herein, including the promotion by the Company of Cardiol Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Cardiol Therapeutic’s Cortalex THC free CBD product now available at...

Cardiol Therapeutics (TSX: CRDL- OTCQX: CRTPF) President and CEO David Elsley joined Steve Darling from Proactive with news the company now has a product on the Medical Cannabis By Shoppers Platform. Elsley telling Proactive, Cortalex a THC-free* extra-strength oral CBD formulation, is now...

1 day, 2 hours ago

2 min read